Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Br J Clin Pharmacol ; 59(3): 298-301, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15752375

RESUMO

AIMS: We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in 20 children with falciparum malaria. METHODS: AQ and DEAQ concentrations were determined with SPE-HPLC method. CYP2C8 genotypes were assessed by PCR-RFLP method. RESULTS: AQ was not detectable beyond day 3 postdose. Cmax for DEAQ was reached in 3.0 days. The mean values for t1/2, MRT, and AUCtotal were 10.1 days, 15.5 days and 4512.6 microg l(-1) day, respectively. All the children were CYP2C8* homozygous. CONCLUSION: Our data are consistent with those previously reported, and the AQ regimen seems pharmacokinetically adequate in the absence of CYP2C8 polymorphism.


Assuntos
Amodiaquina/farmacocinética , Antimaláricos/farmacocinética , Malária Falciparum/metabolismo , Administração Oral , Amodiaquina/administração & dosagem , Antimaláricos/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Criança , Pré-Escolar , Cromatografia Líquida de Alta Pressão , Citocromo P-450 CYP2C8 , Genótipo , Humanos , Lactente , Reação em Cadeia da Polimerase/métodos , Polimorfismo de Fragmento de Restrição
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA